SQSTM1 and neoplasm: Other fusion types, such as SQSTM1-NTRK1, although carried by only one patient with THCA in our study, a recent case report demonstrated that patients carrying SQSTM1-NTRK1 had a 51% reduction in tumor burden after 18 months of treatment with larotrectinib, and this impressive efficacy continued (Bargas et al., 2022).